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Abstract 
 
Background: Tumour transfer/development is one of the more serious risks 
associated with transplantation. The behaviour of a tumour can be unpredictable in 
immunosuppressed recipients. We report a highly sensitive method to monitor tumour 
behaviour in real time in a rodent tumour transplant model. This paper also explores 
the effect of MHC matching on tumour growth among control and immunosuppressed 
hosts.  
Methods: Luciferase expressing Wistar rat kidney tumour cells were transplanted 
into either Wistar or Lewis recipients which mimics a well and poorly matched 
combination to assess the effects of MHC matching on transplanted tumour cells. 
Experimental groups included controls with no immunosuppression and animals 
immunosuppressed with Cyclosporine. The latter group was further divided into a 
continuous treatment group which received four weeks of immunosuppression and a 
treatment withdrawal group where immunosuppression was stopped after two weeks 
to assess the effects of rejection on tumour growth.  
Results: All the tumour cells were rejected in the control animals that received no 
immunosuppression, within 2 weeks among well-matched combination and within 
one week in the poorly matched combination (p 0.001). The transplanted tumour cells 
continued to grow in both well-matched and poorly matched groups who were treated 
with cyclosporine, but growth was significantly faster in the well-matched 
combination (p 0.033). After treatment withdrawal the tumour cells were rejected in 
all the animals of the poorly matched group compared to 50% in well matched 
animals within the four-week study period (p 0.039).  
Conclusion: In the absence of immunosuppression the hosts reject the transplanted 
tumour cells, and the anti-tumour response is stronger when there is a greater 
mismatch in MHC with the recipient. In the presence of Cyclosporine 
immunosuppression the tumour continues to grow, however, after withdrawal of the 
immunosuppression, tumour clearance is quicker in the poorly matched background. 
This data supports the idea of expansion of the donor pool by using kidneys after ex 
vivo resection of small renal tumours and that these organs should be transplanted 
into a less well-matched HLA recipient. We hypothesise that should a tumour 
recurrence occur a poorly matched recipient could clear the tumour through 
withdrawal of immunosuppression.  
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1 Background 
 
Transplantation has revolutionised the treatment of patients with renal failure. It not 
only improves quality of life but also has a significant survival advantage compared 
with dialysis(1). Although graft survival and the absolute number of allografts has 
increased over the past couple of decades, there remains a large gap between the 
number of organs available and potential recipients(2). Over the years new sources of 
organs have been explored but the problem persists and there is still a need to increase 
donor numbers.  
There is a large body of evidence that patients with small renal cell carcinomas (RCC) 
can be treated with nephron sparing surgery (NSS) with comparable outcomes to the 
previous gold standard of radical nephrectomy(3,4). Consequently for a patient 
electing to have their whole kidney removed for a small RCC there is a potential for 
the removal of the tumour and then allotransplantation of the remaining kidney. This 
approach has been utilised by a few groups with good results(5–9). One of the most 
important and perhaps potentially dangerous differences between a urology patient 
that has undergone NSS for a small RCC and a potential allograft recipient of an NSS 
kidney is that transplant recipients are on lifelong immunosuppression. 
Immunosuppressive agents inhibit the natural checks on cancer cells by the immune 
system. It is not known how tumour cells will behave in a HLA incompatible 
immunosuppressed host, if there is any inadvertent transplantation along with such 
restored kidneys. 
In the absence of any immunosuppression the allograft is rejected. Theoretically any 
tumour cells transplanted along with the allograft should be rejected as they both 
originate from the same donor. However, cancerous cells have the ability to make 
themselves less immunogenic thereby evading the donor immune system in the first 
instance and it is not clear how they will behave in a new host (10). 
2  Objectives 
The aim of this study was to establish a rodent tumour transplant model and study the 
effects of immunosuppression on tumour growth. The other main aim was to study 
the effects of acute rejection on tumour cells in a transplantation setting. 
 
3 Study Design and Methods  
3.1 Cell culture 
The tumour cell line, BP36b was acquired from Riken Bio Resource Centre (BRC) 
Cell Bank© Japan. This is a rat kidney tumour cell line derived from male Wistar rats 
that received N-ethyl-N-hydroxyethylnitrosamine (NHEN) in drinking water to 
induce tumour growth. The cell line is stable and maintained its characteristics after 
100 passages over a 3 year period(11). Cells were grown in RPMI 1640 supplemented 
with glutamine and antibiotics (penicillin 10,000 units ml
-1
, streptomycin 10 mg ml
-1
, 
gentamicin 50 g ml-1and amphotericin B 25g ml-1). The doubling time of the cell 
line was consistent with the reported time in the literature (17 hours)(11). 
 
 
 
3.2 Transfection 
For real time in vivo imaging of the tumour cells, the cell line was transfected with a 
commercial lentiviral construct that is stably integrated and constitutively expresses 
the enzyme luciferase for bioluminescence and Green Florescent Protein (GFP) for 
florescence(12,13). Puromycin (10 g ml-1) was used for selection of stable 
transfectants. 
Puromycin supplemented media was replaced every 48-72 hours to select for single 
colonies of stable transfectants. Transfectants were initially assessed by the 
expression of GFP by florescence microscopy. Bioluminescence was determined 
initially by a luminometer and then by direct visualisation using the IVIS® spectrum 
imaging system (Caliper Inc.) (Fig 1).  
 
3.3 Tumour transplantation 
Animals were injected with a fixed number of cells (1.8 x 10
7
) into the right flank 
under Isoflurane anaesthesia after shaving the fur. The animals were anaesthetised in 
the induction chamber of the IVIS spectrum imaging system and then transferred into 
the dark chamber where they were scanned for varying lengths of time (60 -300 
seconds). Animals were kept anaesthetised in the imaging chamber to enable long 
exposure times required to detect even very faint bioluminescent signals. Luciferin 
was injected intraperitoneally at the dose of 150mg/kg 10-15 minutes before scanning 
to allow circulatory distribution throughout the animal before detection. Timing of 
luciferin injection was calculated by plotting the kinetic curve prior to the 
experiments. To compensate for variations in Luciferin distribution, 2-3 images were 
taken of each animal at different time points and the only the image with the strongest 
signal used for further analysis. Regions of interest (ROIs) were the areas of cell 
injection and any other areas with positive signals. The background luminescence was 
calculated for each animal and signal intensity was calculated by subtracting this from 
the ROI value to get the accurate value of signals from the transplanted tumour cells 
(Fig 2). 
 
3.4 Experimental groups 
To study the effects of matching on transplanted tumour growth two different strains 
of rats, Wistar and Lewis were used. Since tumour cells were of Wistar origin, when 
injected into Wistar rats (outbred)(14) this combination served as a well-matched 
group as both the animals were of the same strain. Despite the similarities between the 
tumour cell line and the recipients, these animals were not true syngeneic to the 
tumour cells due to being outbred(15). The other group was of inbred Lewis animals 
that served as a poorly matched group due to transplantation across the strain, leading 
to more marked immunological differences.  
To keep the variables to a minimum, only male Wistar or Lewis rats were used for 
experiments as follows:  
Controls; not receiving any immunosuppression and Cyclosporine (Cyc) group; 
receiving 25mg/kg of Cyc daily via oral gavage. The cyclosporine group was further 
divided into treatment continue group receiving four weeks of continuous 
immunosuppression and the treatment withdrawal group where 
immunosuppression was stopped after 2 weeks to study the effects of rejection on the 
transplanted tumour cells.  All the animals were kept in a clean air conditioned rodent 
area with 12 hour dark/light cycle and were fed standard rodent blocks and with free 
access to tap water. Animals were weighed weekly to adjust the doses of 
Cyclosporine and Luciferin. 
3.5 Statistical analysis 
To detect a five-fold difference in tumour size with a standard deviation of 0.2 with a 
90% certainty and alpha of 0.05 we calculated a sample size of 6 rats per group. 
Statistical analysis was performed with the PASW 18.0.0 (IBM Inc. 2009) and 
GraphPad prism (Version 5.04 GraphPad Inc.) softwares. The normality of the data 
was tested prior to performing either ANOVA or non-parametric Mann-Whitney tests 
accordingly.  
 
4 Results 
4.1 Controls  
The kinetics of tumour rejection was first studied in the absence of 
immunosuppression. With well-matched animals there were still good signals at 
week one, but all the animals subsequently rejected the tumours cells and lost signal, 
even after long exposure, at week two. All poorly matched animals rejected the 
tumour cells and lost signal within the first week (p <0.001 at week 1) (Fig 3).  
 
 
 
4.2 Cyclosporine treatment 
The effect of Cyclosporine on the rate of rejection was then studied in well-matched 
and poorly matched groups. These groups were further sub-divided into the animals 
receiving the immunosuppression for a full four weeks and the animals receiving the 
treatment for 2 weeks followed by treatment withdrawal. The rats in the treatment 
withdrawal group were scanned as normal for the study period of four weeks before 
euthanasia.  
The tumour continued to grow in both the well and poorly matched animals when 
immunosuppressive treatment was continuous. There was no significant difference in 
the growth of the transplanted tumour cells in the initial three weeks of the study, 
however growth was significantly faster in the well matched Wistar animals 
compared to the poorly matched Lewis rats (p 0.033) by week 4 (Fig 4). 
 In 4 of 8 animals of the well-matched Wistar rats after treatment withdrawal tumour 
signal could still be detected at 2 weeks post treatment withdrawal. However, in the 
poorly matched Lewis animals the whole group had rejected the tumour by the end of 
the study period (two weeks post treatment withdrawal) (p 0.039) (Fig 5 & 6). 
 
5 Discussion  
Better immunosuppressive therapies have resulted in long allograft survival with 
reduced side effects. The risk of cancer development, however, even from standard 
allografts without any obvious donor malignancy still persists. The initial results of 
function and recurrence rates from transplanting restored organs after ex vivo 
resection of tumour remain favourable(16) from the limited data available so far. 
However, there remain some serious questions regarding the safety of such an 
approach in immunocompromised hosts. The behaviour of a tumour in a transplant 
setting can be unpredictable since all patients will be immunocompromised to some 
degree in order to prevent graft rejection. Consequently any study, which investigates 
the effect of tumour cell growth in a transplant model to investigate whether the 
immunosuppressive treatment, or MHC mismatch has any bearing on tumour growth 
is worthwhile. 
The stability of the tumour cells (BP36B) used for our study has been demonstrated 
by the observation that the cells retained their properties after multiple passages(11). 
The cells being of Wistar origin made it possible for us to study the effects of tissue 
matching on the tumour behaviour by using outbred Wistar and inbred Lewis strains 
for implantation. When these cells were injected in the Lewis animals, they behaved 
as a poorly matched group as the transplantation was between two different strains 
with marked immunological differences. When these cells were injected into the 
Wistar rats, they behaved as relatively well-matched combination when compared to 
the Lewis animals but strictly speaking they could not be classified as syngeneic 
transplantation. This is because of inter-individual variations in RT1 (rat major 
histocompatibility complex) among any outbred strain of the rats(15,17,18). This 
slight variation made our tumour model closely reflective of scenarios in human 
transplantation; as even the very well matched individuals (excluding identical twins-
syngeneic transplantation) would have subtle differences in histocompatibility loci 
due to the very wide variations in the HLA haplotype(19).  
Tumour cells injected into hosts normally take a long time to become palpable. Even 
cells with short doubling times often take a long time to become clinically significant 
and enable accurate measurements. The BP36B cells, used in our study took two 
months to establish when transplanted in immunocompromised nude mice(11). 
Consequently we decided to transfect the tumour cells with luciferase in order to 
detect and monitor tumour growth by sensitive bioluminescent imaging techniques. 
Furthermore, the quantitative measurements made by this method were objective and 
less susceptible to human error and bias since tumour load was calculated 
computationally by signal intensity from the injected tumour cells rather than the 
more subjective method of visually grading the tumour size. 
The behaviour of well and poorly matched transplanted tumour cells under conditions 
of immunosuppression and rejection (treatment withdrawal) has potential important 
clinical implications. The tumour cells were, as expected, rejected in the absence of 
any immunosuppression in both groups of animals since there are likely to be some 
differences between the donor and recipient even in the well-matched combination. 
However, the time taken for the poorly matched animals to reject the tumour was 
significantly shorter (p 0.001), and it is likely that this was due in part to the stronger 
allogeneic response having an anti-tumour effect. Similar results were noted when the 
immunosuppression was withdrawn midway in the study period to monitor the effects 
of rejection (p 0.039). All the Lewis animals rejected the tumour two weeks after 
withdrawal while only half in the well-matched group did so. The clinical significance 
of this finding is that if were we to transplant kidneys after ex vivo resection of T1a 
tumours, then perhaps choosing a less well-matched donor recipient combination 
would be preferable. This would mean, should a recurrence occur in the recipient, 
simply withdrawing the immunosuppression (with transplant nephrectomy) may aid 
“rejection” of extra renal tumour cells(20).  This was the approach utilised by Nicol et 
al. in their series, although they were not able to test this hypothesis as the only 
patient developing recurrence in their series declined any further treatment(7).  
The other clinically significant implication is the fact that under standard 
immunosuppression the tumour continued to grow. There were subtle but statistically 
significant (p 0.033) differences in the rate of growth, with higher rate of tumour 
growth in well-matched animals. However, in both strains by the end of study period 
the signal intensity was high and in the majority of immunosuppressed rats the 
tumours were palpable. Therefore, the risk of unchecked tumour growth and perhaps 
metastasis would be a real concern should a tumour be transplanted inadvertently with 
a restored organ. The behaviour of tumours with immunosuppression using more 
contemporary immunosuppressants that have reported anti-neoplastic activity, such as 
Rapamycin and Leflunomide, needs to be investigated. Such immunosuppressive 
agents may prove to be effective in preventing recurrence or eliminate the cancer cells 
should they be transplanted inadvertently. A strategy to transplant these kidneys into 
less well-matched recipients and to use non-calcineurin inhibitor immunosuppression 
may provide the best outcomes.  
 
6 Conclusions 
Subtle variations in the growth of the tumour cells based on MHC-dependent 
differences in various experimental conditions were detected with great accuracy 
using the IVIS spectrum imaging system. There are two clinically relevant deductions 
of our experiments. Firstly, transplanted tumour cells continue to grow unchecked in 
immunosuppressed hosts. This finding makes it of paramount importance that any 
kidney transplanted after ex vivo resection must be devoid of any tumour load. 
Secondly, poorly matched combination of donor and hosts were significantly better in 
rejecting any donor-derived tumour if immunosuppression was withdrawn in this 
animal model. Should a recurrence occur in a clinical situation after such 
transplants, it might be better to have less well matched donor recipient combination 
so that host’s own immune system can be used at least in part to reject the 
transplanted tumour by withdrawal of immunosuppression.  
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Legends to Figures 
 
Fig 1.   IVIS spectrum image of non transfected cells (Left) and transfected 
cells (right).  The system produces a heat map image that can be compared to the 
scale seen to the right of the image and the intensity of the luminescence calculated 
(P/sec/cm2/sr). 
Fig 2.  Day 0 IVIS spectrum image of Wistar rat after injection of transfected 
tumour cells into the right flank. Imaging was performed 15 minutes after intra-
peritoneal injection of Luciferin for maximum signal intensity. Region of interest 
(ROI, solid red circle) is the area of positive signals from the injection site while the 
background bioluminescence (dotted red circle) is calculated for each image to 
calculate bioluminescence.  
Fig 3.   Graph showing the time taken for rejection of tumour cells among 
control animals without immunosuppression. Well-matched Wistar animals (green) 
took two weeks to reject the tumour load while poorly matched Lewis (blue) animals 
rejected the tumour load within one week (P < 0.001) (the error bars representing 
standard error of mean).  
Fig 4.  Cyclosporine treatment continue group: Comparison between well 
matched Wistar (green) and poorly matched Lewis (blue) groups. Transplanted 
tumour cells continued to grow between both the groups but again the growth was 
stronger in well-matched animals compared to the poorly matched combination. 
Fig 5.   Effect of treatment withdrawal in well matched and poorly matched 
combination groups. All the poorly matched animals (blue) rejected the transplanted 
tumour cells within four weeks of study period as opposed to only 50% in well-
matched Wistar (green) during the same study period.  
Fig 6.   Serial IVIS scans of Lewis rats: At the end of 2 weeks of 
immunosuppression (left), 1 and 2 week post treatment withdrawal (middle and right). 
Tumour continued to grow when animals were kept on cyclosporine 
immunosuppression. With treatment withdrawal there has been steady rejection of 
tumour cells till all the injected cells were destroyed (significantly stronger rejection 
than well matched combination of Wistar animals). 
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